• Publications
  • Influence
Representation of African-Americans, Hispanics, and whites in National Cancer Institute cancer treatment trials.
This study shows that the NCIclinical trials are, as a whole, racially/ethnically representative of the American population and suggests that there is equal access to NCI clinical trials.
Retinoids in cancer therapy.
The antitumor activity demonstrated for retinoids (especially RA) alone and in combination with other agents supports the need for targeted phase II trials to define the spectrum of responsive tumors and for laboratory studies to further delineate the biologic mechanisms associated with therapeutic responses.
A reevaluation of nonhormonal cytotoxic chemotherapy in the treatment of prostatic carcinoma.
It is suggested that the appropriate control arm for phase III testing in endocrine-resistant patients continues to be a no chemotherapy control arm consisting of a best symptomatic care or a uniformly applied second-line endocrine manipulation.
A randomized trial of continuous intravenous versus hepatic intraarterial floxuridine in patients with colorectal cancer metastatic to the liver: the Northern California Oncology Group trial.
The study objectives were to compare the hepatic response rate, time to hepatic progression, and toxicity for the two treatment arms, and to adopt a policy of early dosage reduction, treatment interruption, or termination of therapy for persistent elevations in alkaline phosphatase.
Representation of older patients in cancer treatment trials.
All major Phase II and III clinical trials that recently were closed, still are active, or now are in review that address the clinical care of this important segment of the U.S. population are described.
Representation of older patients in cancer treatment trials
To determine the representation of the elderly in clinical trials, the 1992 accrual of the National Cancer Institute (NCI)‐sponsored Clinical Cooperative Group treatment trials (which included more than 8000 elderly patients) for the aforementioned sites was compared with the 1990 incidence data.
Paclitaxel activity in heavily pretreated breast cancer: a National Cancer Institute Treatment Referral Center trial.
Paclitaxel's activity in this multiinstitutional trial in heavily pretreated patients confirms the encouraging results attained in single-institution trials.